Literature DB >> 22721796

SEOM guidelines for cervical cancer.

Ana Oaknin1, Isabela Díaz de Corcuera, Víctor Rodríguez-Freixinós, Fernando Rivera, José María del Campo.   

Abstract

Cervical cancer (CC) is the second most common cancer worldwide, with a well known origin, infection by high-risk human papilloma virus. Although screening programmes have led to a relevant reduction in the incidence and mortality due to CC in developed countries, it is still an important cause of mortality in young women in undeveloped countries. Clinical stage is the most relevant prognostic factor in CC and the standard of care is still based on it. In early stages, the primary treatment is surgery or radiotherapy, whereas concomitant chemo-radiotherapy is the conventional approach in locally advanced stage. In the setting of recurrent or metastatic CC the treatment is largely palliative, so it is important to develop new therapeutic strategies.

Entities:  

Mesh:

Year:  2012        PMID: 22721796     DOI: 10.1007/s12094-012-0834-y

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  9 in total

1.  Radical trachelectomy in early stage carcinoma of the cervix: outcome as judged by recurrence and fertility rates.

Authors:  J H Shepherd; T Mould; D H Oram
Journal:  BJOG       Date:  2001-08       Impact factor: 6.531

2.  Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix.

Authors:  Alfonso Dueñas-González; Juan J Zarbá; Firuza Patel; Juan C Alcedo; Semir Beslija; Luis Casanova; Pittayapoom Pattaranutaporn; Shahid Hameed; Julie M Blair; Helen Barraclough; Mauro Orlando
Journal:  J Clin Oncol       Date:  2011-03-28       Impact factor: 44.544

Review 3.  Stage IB squamous cancer of the cervix: the choice of treatment.

Authors:  G Delgado
Journal:  Obstet Gynecol Surv       Date:  1978-03       Impact factor: 2.347

4.  Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study.

Authors:  Harry J Long; Brian N Bundy; Edward C Grendys; Jo Ann Benda; D Scott McMeekin; Joel Sorosky; David S Miller; Lynne A Eaton; James V Fiorica
Journal:  J Clin Oncol       Date:  2005-05-23       Impact factor: 44.544

5.  Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix.

Authors:  W A Peters; P Y Liu; R J Barrett; R J Stock; B J Monk; J S Berek; L Souhami; P Grigsby; W Gordon; D S Alberts
Journal:  J Clin Oncol       Date:  2000-04       Impact factor: 44.544

Review 6.  Cervical cancer.

Authors:  Steven E Waggoner
Journal:  Lancet       Date:  2003-06-28       Impact factor: 79.321

7.  Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study.

Authors:  David H Moore; John A Blessing; Richard P McQuellon; Howard T Thaler; David Cella; Jo Benda; David S Miller; George Olt; Stephanie King; John F Boggess; Thomas F Rocereto
Journal:  J Clin Oncol       Date:  2004-08-01       Impact factor: 44.544

8.  Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study.

Authors:  Bradley J Monk; Michael W Sill; D Scott McMeekin; David E Cohn; Lois M Ramondetta; Cecelia H Boardman; Jo Benda; David Cella
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544

Review 9.  Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials.

Authors: 
Journal:  J Clin Oncol       Date:  2008-11-10       Impact factor: 44.544

  9 in total
  8 in total

1.  SEOM clinical guidelines: a consolidated project.

Authors:  Juan J Cruz Hernández; César A Rodríguez
Journal:  Clin Transl Oncol       Date:  2012-07       Impact factor: 3.405

2.  Molecular biomarkers in the decision of treatment of cervical carcinoma patients.

Authors:  A Valenciano; L A Henríquez-Hernández; M Lloret; B Pinar; P C Lara
Journal:  Clin Transl Oncol       Date:  2013-02-22       Impact factor: 3.405

3.  What is the future burden of HPV-related cancers in Spain?

Authors:  D L B de Souza; M P Curado; M M Bernal; J Jerez Roig
Journal:  Clin Transl Oncol       Date:  2013-06-20       Impact factor: 3.405

4.  Can LBC Completely Replace Conventional Pap Smear in Developing Countries.

Authors:  Vasundhara Kamineni; Priti Nair; Ashok Deshpande
Journal:  J Obstet Gynaecol India       Date:  2018-05-18

5.  No Value for Routine Chest Radiography in the Work-Up of Early Stage Cervical Cancer Patients.

Authors:  Jacob P Hoogendam; Ronald P Zweemer; Helena M Verkooijen; Pim A de Jong; Maurice A A J van den Bosch; René H M Verheijen; Wouter B Veldhuis
Journal:  PLoS One       Date:  2015-07-02       Impact factor: 3.240

6.  A comparison of liquid-based cytology with conventional Papanicolaou smears in cervical dysplasia diagnosis.

Authors:  Fatemeh Haghighi; Nahid Ghanbarzadeh; Marziee Ataee; Gholamreza Sharifzadeh; Javid Shahbazi Mojarrad; Fatemeh Najafi-Semnani
Journal:  Adv Biomed Res       Date:  2016-10-26

7.  Management and Care of Women With Invasive Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Clinical Practice Guideline.

Authors:  Linus T Chuang; Sarah Temin; Rolando Camacho; Alfonso Dueñas-Gonzalez; Sarah Feldman; Murat Gultekin; Vandana Gupta; Susan Horton; Graciela Jacob; Elizabeth A Kidd; Kennedy Lishimpi; Carolyn Nakisige; Joo-Hyun Nam; Hextan Yuen Sheung Ngan; William Small; Gillian Thomas; Jonathan S Berek
Journal:  J Glob Oncol       Date:  2016-05-25

8.  Antitumor activity of tanshinone and its nanoparticles on U14 cervical carcinoma-bearing mice.

Authors:  Ya Di; Qingjie Meng; Hongwei Yang; Kun Li; Liyan Cao; Ming Shi; Zhanzhao Fu; Hao Di
Journal:  Nanobiomedicine (Rij)       Date:  2016-12-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.